Short bowel syndrome.
Nine patients with short bowel syndrome and high intestinal output received octreotide either intravenously (50-100 micrograms t.i.d.) or subcutaneously (100 micrograms b.i.d.) on 2 test days. In the 6 patients with net secretory output, there was a reduction in mean daily intestinal output of 0.5-5.0 kg; total daily intestinal output of sodium and potassium was also reduced significantly. Of the 3 patients with a net absorptive state, there was a worsening of output in 2 and no improvement occurred in the other. Two patients with net secretory output received long-term octreotide therapy, allowing a reduction in daily intravenous fluid intake of 1.0-1.5 litres.
Nightingale
J M
JM
St Mark's Hospital, London, UK.
Walker
E R
ER
Burnham
W R
WR
Farthing
M J
MJ
Lennard-Jones
J E
JE
D000284:Administration, Oral; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000187:drug effects; D008286:Malabsorption Syndromes / Q000188:drug therapy*; D008875:Middle Aged; D012778:Short Bowel Syndrome / Q000188:drug therapy* / Q000209:etiology; D013004:Somatostatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D013004:Somatostatin